Drug profile

The FDA adverse-event record for Fenbendazol Oral Paste

159 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Fenbendazol Oral Paste. See the species affected, top reactions, and outcomes below.

159
adverse-event reports
10.7%
death-coded share
Horse
most-reported species
19
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
159
Total Reports
17
Deaths Reported
10.7%
Death Rate

Active Ingredients

Fenbendazol Oral Paste

Administration Routes

OralUnknown

Species Affected

Horse 68
Unknown 39
Dog 38
Cattle 4
Cat 3
Human 3
Pig 1
Turkey 1
Mule 1
Sheep 1

Most Affected Breeds

Unknown 43
Quarter Horse 21
Horse (unknown) 13
Crossbred Canine/dog 11
Thoroughbred 10
Paint 4
Mixed (Horse) 3
Dog (unknown) 3
Shepherd Dog - Australian 3
Terrier - Yorkshire 3

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 19
INEFFECTIVE, STRONGYLES 14
Product problem 10
Uncoded sign 9
Underfilling, Container 9
Underfilling, Package 8
Ataxia 8
Drug administration error 8
Product Defect, General 8
Death 8
Weight loss 7
Diarrhoea 7

Outcome Breakdown

Ongoing
48 (38.4%)
Recovered/Normal
37 (29.6%)
Outcome Unknown
20 (16.0%)
Died
11 (8.8%)
Euthanized
6 (4.8%)
Recovered with Sequela
3 (2.4%)

Fenbendazol Oral Paste Adverse Event Insights

159 reports name Fenbendazol Oral Paste; 17 recorded a death outcome (10.7% of reported events, not a population-level mortality rate). Active ingredient: Fenbendazol Oral Paste. Administration routes: Oral, Unknown.

By species: Horse (68 reports), Unknown (39 reports), Dog (38 reports). By breed: Unknown (43), Quarter Horse (21), Horse (unknown) (13).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (19), INEFFECTIVE, STRONGYLES (14), Product problem (10), Uncoded sign (9). Outcome, 125 coded reports: Ongoing leads at 38.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.